Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly
Status:
Unknown status
Trial end date:
2021-02-01
Target enrollment:
Participant gender:
Summary
Octreotide capsule is a novel, orally-administered formulation of the commercially-available
injectable drug octreotide. In a recent phase 3 trial, oral octreotide capsules demonstrated
sustained biochemical response up to 13 months in patients with acromegaly previously managed
with somatostatin analog injections (ref).
The purpose of this study is to compare the efficacy safety and patient reported outcomes
between oral octreotide capsules and injectable somatostatin analogs.